The shelf
Every compound on the shelf.
32 entries — structural biochemistry, primary literature, third-party COAs. No health claims. Everything here is 35% off, applied automatically at checkout.
NNMT (nicotinamide N-methyltransferase) inhibitor
5-Amino-1MQ
A small-molecule compound (5-amino-1-methylquinolinium iodide) — not a peptide, technically a substrate-mimetic inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Characterized in the 2010s primarily by Alessio Neri and Robert Messing's group and other metabolic-disease labs.
Read the full note →
Human growth-hormone fragment (177–191)
AOD-9604
A synthetic peptide corresponding to the C-terminal 15-amino-acid fragment of human growth hormone (residues 177–191), with an added N-terminal tyrosine for stability. Originally developed by Metabolic Pharmaceuticals in the late 1990s as a putative fat-metabolism candidate lacking the growth-promoting activity of full-length hGH.
Read the full note →
Gastric pentadecapeptide
BPC-157
A synthetic 15-amino-acid peptide fragment corresponding to a sequence in Body Protection Compound (BPC), a protein produced in the stomach lining. First characterized by Predrag Sikirić's group at the University of Zagreb in the early 1990s.
Read the full note →
GHRH analog + GHRP
CJC-1295 / Ipamorelin (No DAC)
A blend of two peptides: CJC-1295 (a modified 30-residue GHRH analog with amino acid substitutions for enhanced stability) and Ipamorelin (a pentapeptide growth-hormone secretagogue receptor agonist). Sold in the 'No DAC' configuration — the drug affinity complex modification is omitted, shortening plasma half-life.
Read the full note →
Angiotensin IV analog (hexapeptide)
Dihexa
A hexapeptide (N-hexanoic-Tyr-Ile-(6) amino hexanoic amide) engineered as an orally-bioavailable analog of the angiotensin IV fragment 3-8. Developed by Joseph Harding and colleagues at Washington State University as a research tool for the hepatocyte growth factor / c-Met pathway in cognitive-decline models.
Read the full note →
Delta Sleep-Inducing Peptide (nonapeptide)
DSIP
A nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated by Marcel Monnier's group at the University of Basel in the mid-1970s, from cerebral venous blood of rabbits during electrically-induced delta-wave EEG sleep. Never developed as a pharmaceutical; remains a research-only compound.
Read the full note →
Synthetic tetrapeptide bioregulator
Epithalon
Alanyl-glutamyl-aspartyl-glycine (Ala-Glu-Asp-Gly) — a synthetic tetrapeptide developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, first published in the mid-1990s. Also spelled Epitalon.
Read the full note →
Copper tripeptide
GHK-Cu
A copper-binding tripeptide — glycyl-L-histidyl-L-lysine coordinated to a divalent copper ion. Isolated from human plasma by Loren Pickart, 1973.
Read the full note →
Three-peptide combination stack (BPC-157 + TB-500/TB-4 + GHK-Cu)
GLOW
A vendor-formulated combination of three research peptides — BPC-157 (a synthetic pentadecapeptide), TB-500 (a 17-residue fragment of thymosin β-4), and GHK-Cu (the copper-tripeptide glycyl-histidyl-lysine). Sold in a single lyophilized vial at roughly a 5-to-1-to-1 mass ratio favoring GHK-Cu (approximately 52 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-4 per 70 mg vial, per the vendor's lot COAs). Each constituent has its own literature record; the combination itself is a marketing construct, not a published research protocol.
Read the full note →
Endogenous tripeptide antioxidant
Glutathione
γ-L-glutamyl-L-cysteinyl-glycine — a tripeptide central to intracellular redox chemistry. Not a novel research compound: characterized biochemically since the late 1800s, structurally by Frederick Gowland Hopkins, 1921.
Read the full note →
Modified IGF-1 analog (Long R3 variant)
IGF-1 LR3
An 83-amino-acid analog of insulin-like growth factor 1 with an N-terminal 13-residue extension (from methionyl-porcine growth hormone) and a single Arg-for-Glu substitution at position 3. The Long R3 modification substantially reduces binding to circulating IGF-binding proteins, extending plasma half-life relative to native IGF-1.
Read the full note →
Selective GHSR agonist (GHRP)
Ipamorelin
A synthetic pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — that acts as a selective agonist of the growth-hormone secretagogue receptor (GHSR / ghrelin receptor). Discovered and characterized by Kirsten Raun and colleagues at Novo Nordisk in the mid-1990s.
Read the full note →
Hypothalamic GPR54 agonist
Kisspeptin
A family of peptides (Kisspeptin-54, -14, -13, -10) derived from the KISS1 gene product. Discovered as a metastasis-suppressor gene in 1996, later shown to encode the endogenous ligand of the GPR54/KISS1R receptor and the upstream master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Central hypothalamic role clarified in the early 2000s by de Roux and Seminara.
Read the full note →
Four-peptide combination stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW
A vendor-formulated combination of four research peptides — BPC-157 (a synthetic pentadecapeptide), TB-500 (a 17-residue fragment of thymosin β-4), GHK-Cu (the copper-tripeptide glycyl-histidyl-lysine), and KPV (the C-terminal α-MSH tripeptide lysine-proline-valine). Sold in a single lyophilized vial at approximately a 5-to-1-to-1-to-1 mass ratio favoring GHK-Cu (roughly 52 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV per 80 mg vial, per the vendor's lot COAs). Each constituent has its own literature record; the combination itself is a marketing construct — essentially GLOW with KPV added — not a published research protocol.
Read the full note →
α-MSH tripeptide fragment
KPV
Lysine-proline-valine — a synthetic tripeptide corresponding to the C-terminal three residues of α-melanocyte stimulating hormone (α-MSH). The parent α-MSH is a 13-residue neuropeptide characterized across decades of endocrine literature.
Read the full note →
Human cathelicidin peptide
LL-37
The 37-amino-acid mature peptide cleaved from human cathelicidin antimicrobial protein (hCAP-18), encoded by the CAMP gene. The only cathelicidin in humans. Broadly characterized since the 1990s for direct antimicrobial activity and, later, for immunomodulatory signaling through formyl-peptide receptor 2 (FPR2) and other receptors.
Read the full note →
Cyclic α-MSH analog (13-residue)
Melanotan I
A cyclic 13-amino-acid analog of α-melanocyte stimulating hormone (α-MSH), developed at the University of Arizona (Hadley, Hruby, Sawyer group) in the 1980s. Corresponds to the INN afamelanotide, which is FDA-approved for a single specific clinical indication (erythropoietic protoporphyria) under a branded prescription formulation held by Clinuvel Pharmaceuticals.
Read the full note →
Cyclic α-MSH analog
Melanotan II
A cyclic synthetic 7-amino-acid analog of α-melanocyte stimulating hormone (α-MSH). Originally developed at the University of Arizona (Hadley, Hruby group) in the 1980s. Not FDA-approved; distinct from Melanotan I (afamelanotide), which IS FDA-approved under its own branded formulation for erythropoietic protoporphyria.
Read the full note →
Mitochondrial-derived peptide
MOTS-c
A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of the first recognized 'mitochondrial-derived peptides.' Identified and characterized by Changhan Lee, Pinchas Cohen, and colleagues at USC, published 2015 in Cell Metabolism.
Read the full note →
Pyridine coenzyme
NAD+
Nicotinamide adenine dinucleotide — a coenzyme central to oxidation-reduction reactions in every living cell. Identified by Harden and Young, 1906; structural characterization completed by Warburg, 1936.
Read the full note →
Cyclic melanocortin agonist
PT-141
A cyclic 7-amino-acid peptide melanocortin-receptor agonist developed by Palatin Technologies from the α-MSH template. The compound corresponds to the INN bremelanotide, which is FDA-approved as a prescription drug for a single specific clinical indication.
Read the full note →
GIP + GLP-1 + glucagon triple agonist
Retatrutide
A synthetic 39-amino-acid peptide (also known as LY3437943) that binds three receptors: GIP, GLP-1, and glucagon. Investigational Eli Lilly compound; not FDA-approved as of writing.
Read the full note →
Synthetic tuftsin analog (heptapeptide)
Selank
A synthetic 7-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — an analog of the immunomodulatory tetrapeptide tuftsin extended with proline-glycine-proline for stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside Semax. Approved as a prescription anxiolytic in the Russian Federation; not FDA-approved.
Read the full note →
GLP-1 receptor agonist
Semaglutide
A 31-residue analog of human GLP-1 (~94% sequence homology) with a C18 fatty-diacid chain attached via a linker — the modification drives reversible albumin binding and extended plasma half-life. The GLP-1 receptor agonist researchers reference by this name.
Read the full note →
Synthetic ACTH(4-10) analog with Pro-Gly-Pro tail
Semax
A synthetic 7-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) — an analog of the 4-10 fragment of ACTH extended at the C-terminus with a proline-glycine-proline sequence for peptidase resistance. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1980s. Approved in the Russian Federation as a prescription drug; not FDA-approved.
Read the full note →
GHRH analog (29-residue N-terminal fragment)
Sermorelin
A synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone (GHRH 1-29 NH₂) — the shortest N-terminal fragment retaining full biological activity at the GHRH receptor. Was previously FDA-approved as a prescription drug for pediatric growth-hormone deficiency; that branded formulation was commercially discontinued in the United States in 2008 (withdrawn from the market, not for safety reasons).
Read the full note →
Thymosin β-4 fragment
TB-500
A synthetic peptide corresponding to the acetylated N-terminal fragment of thymosin β-4 (TMSB4X), a 43-amino-acid actin-binding protein originally isolated from thymic tissue. Characterized by Allan Goldstein and colleagues at George Washington University, 1980s onward.
Read the full note →
GHRH analog
Tesamorlin
A synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), stabilized by a trans-3-hexenoyl modification at the N-terminus. Developed by Theratechnologies. FDA-reviewed 2010 for a single specific clinical indication (published in the FDA label).
Read the full note →
Thymic 28-residue peptide (acetylated)
Thymosin Alpha-1
A 28-amino-acid N-acetylated peptide originally isolated from thymic tissue by Allan Goldstein and Abraham White in the mid-1970s at what became George Washington University. The compound corresponds to the INN thymalfasin, which is approved as a prescription drug in roughly 35 countries for hepatitis B, hepatitis C, and certain immunocompromised patient populations — but is NOT FDA-approved in the United States.
Read the full note →
GIP + GLP-1 dual agonist
Tirzepatide
A 39-residue synthetic linear peptide engineered as a dual receptor agonist at both the GIP receptor and the GLP-1 receptor. Developed by Eli Lilly; the dual incretin-receptor agonist researchers reference by this name.
Read the full note →
Vasoactive Intestinal Peptide (28 residues)
VIP
Vasoactive Intestinal Peptide — a 28-amino-acid signaling peptide in the secretin/glucagon superfamily. Isolated by Said and Mutt from porcine duodenum in 1970. Widely characterized as a neurotransmitter, neuromodulator, and immunomodulator across five decades of literature.
Read the full note →
Two-peptide combination stack (BPC-157 + TB-500/TB-4)
Wolverine Stack
A vendor-formulated combination of two research peptides — BPC-157 (a synthetic 15-amino-acid pentadecapeptide derived from a sequence in Body Protection Compound, a stomach-lining protein) and TB-500 (a 17-residue fragment of the endogenous protein thymosin β-4). Each constituent has its own decades-long literature record; the combination itself is a marketing construct, not a published research protocol. Sold in a single lyophilized vial at approximately a 1-to-1 mass ratio (5.32 mg BPC-157 + 5.11 mg TB-500 per 10 mg vial, per the vendor's lot COA).
Read the full note →
Method
Every entry starts with the basics — chemical name, what class of molecule it is, when it was discovered, and who studies it. The research links go straight to Google Scholar and PubMed, so you can read the papers yourself. Every vendor claim comes from a lot-specific third-party COA. We do not sell, dispense, or prescribe. See the full method note.